A股異動 | 中藥股集體上漲 新冠病毒感染者居家中醫藥干預指引公佈
格隆匯12月12日丨中藥股集體上漲,大理藥業、貴州百靈、精華製藥、盤龍製藥漲停,上海凱寶、龍津藥業漲8%,白雲山、振東藥業漲7%;港股白雲山、中智藥業漲7%,健倍苗苗、中國中藥漲2%,神威醫藥、華潤醫藥漲1%。12月11日,國家中醫藥管理局中醫疫病防治專家委員會昨日發佈《新冠病毒感染者居家中醫藥干預指引》。此外,國務院聯防聯控機制綜合組11日發佈的《關於印發依託縣域醫共體提升農村地區新冠肺炎醫療保障能力工作方案的通知》指出,各地要按照鄉鎮衞生院服務人口的15%-20%配齊配足中藥、解熱、止咳等對症治療藥物和抗原檢測試劑盒。上海證券表示,奧密克戎變異株及其進化分支的致病力和毒力明顯減弱,引起重症和死亡的比例明顯較低,而我國新冠重症及其關聯死亡處於較低水平,這與國家積極的預防策略和統籌優質救治力量有關,中醫藥也發揮了積極的作用。此外,中醫藥在治療咳嗽、炎症等臨牀症狀中往往有不同於西藥的療效,未來在緩解新冠臨牀症狀中或將發揮更加重要的作用。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.